Histologic changes in the rat prostate cancer model after treatment with somatostatin analogs and D‐Trp‐6‐LH‐RH

The Prostate

Volumn 12, Issue 1, 1988, Pages 85-98

  Zalatnai, Attila ^b   Paz‐Bouza, Jose I ^b   Redding, Tommie W ^a   Schally, Andrew V ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

histomorphometry; luteinizing hormone releasing hormone agonist; pathology of prostate tumor

Indexed keywords

DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLCYSTEINYLTHREONINAMIDE 2,7 DISULFIDE; VAPREOTIDE;

ANIMAL; ANIMAL CELL; ANIMAL EXPERIMENT; HISTOLOGY; PROSTATE CANCER; RAT;

ADENOCARCINOMA; ANIMAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; EPITHELIUM; GONADORELIN; LUTEINIZING HORMONE; MALE; ORGAN WEIGHT; PROLACTIN; PROSTATE; PROSTATIC NEOPLASMS; RATS; SOMATOSTATIN; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.; TESTIS; TESTOSTERONE; TRIPTORELIN;

EID: 0023917523     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.2990120111     Document Type: Article

References (25)

1. Animal models for the study of prostatic cancer
2. Characterization of the Dunning R3327 prostatic adenocarcinoma: An appropriate animal model for prostatic cancer
3. Androgen, estrogen, and progesterone receptors of the R3327H Copenhagen rat prostatic tumor
4. The presence of LHRH‐like receptors in Dunning R3327H prostate tumors
5. 6 analogue of luteinizing hormone‐releasing hormone
6. 6] luteinizing hormone‐releasing hormone from injectable microcapsules
7. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormonereleasing hormone agonist
8. Treatment of advanced prostatic carcinoma with D‐Trp‐6‐LH‐RH
9. Treatment of prostatic cancer with D‐Trp‐6‐LH‐RH: Plasma hormone levels after daily subcutaneous injections and periodic administration of delayed‐release preparations
10. Investigation of the combination of the agonist D‐Trp‐6‐LH‐RH and the antiandrogen flutamide in the treatment of Dunning R‐3327H prostate cancer model
11. Role of prolactin in modulating the effects of tamoxifen on growth of the Dunning R3327 rat prostate adenocarcinoma
12. Hormonal and chemotherapeutic treatment of prostatic carcinoma; Dunning adenocarcinoma of the prostate in Copenhagen‐Fischer rats
13. Combination of long‐acting microcapsules of the D‐tryptophan‐6 analog of luteinizing hormone‐releasing hormone with chemotherapy: Investigation in the rat prostate cancer model
14. Combination of a long‐acting delivery system for luteinizing hormone‐releasing hormone agonist with Novantrone chemotherapy: Increased efficacy in the rat prostate cancer model
15. Histological findings in the rat prostate cancer model during treatment with a luteinizing hormone‐releasing hormone agonist and Novantrone
16. Endocrine, gastrointestinal, and antitumor activity of somatostatin analogues
17. Somatostatin analogs as adjuncts to agonists of luteinizing hormone‐releasing hormone in the treatment of experimental prostate cancer
18. The effect of estrone‐progesterone treatment on cell proliferation kinetics of hormone‐dependent GR mouse mammary tumors
19. Synthesis and biological activity of highly potent octapeptide analogs of somatostatin
20. Proliferation of Dunning R‐3327 rat prostatic adenocarcinoma and of its sublines (CUA and CUB)
21. Stability of sublines in the R3327‐H rat prostatic tumor
22. Chromosomal changes associated with progression of the Dunning R‐3327 rat prostatic adenocarcinoma system
23. Radioimmunoassay for 6‐D‐tryptophan analog of luteinizing hormone‐releasing hormone: Measurement of serum levels after administration of long‐acting microcapsule formulations
24. Growth factors and cancer
25. Purification and partial characterization of prostate‐derived growth factor